Continuous 5-fluorouracil in the treatment of breast cancer (Q36079497)

12 August 2017

2 references

17 June 2019

20 October 2022

Continuous 5-fluorouracil in the treatment of breast cancer (English)

1 reference

12 August 2017

2 references

17 June 2019

20 October 2022

1 reference

PubMed publication ID

8018521

author name string

Cameron DA

series ordinal

1

1 reference

12 August 2017

Gabra H

series ordinal

2

1 reference

12 August 2017

Leonard RC

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 1994

5 references

British Journal of Cancer

12 August 2017

13 March 2019

3 April 2019

17 June 2019

20 October 2022

5 references

12 August 2017

13 March 2019

3 April 2019

17 June 2019

20 October 2022

70

1 reference

12 August 2017

1

1 reference

12 August 2017

120-124

1 reference

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Chemotherapy of carcinoma of the stomach

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Chemotherapy of advanced breast cancer: outcome and prognostic factors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Continuous infusion chemotherapy: a critical review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Fluorouracil: biochemistry and pharmacology

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Systemic therapy in resectable breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033324

Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity

23 September 2018

1 reference

12 December 2020

Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation

1 reference

12 December 2020

Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion

1 reference

12 December 2020

Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes

1 reference

12 December 2020

Phase I study of protracted venous infusion of 5-fluorouracil

1 reference

12 December 2020

Ambulatory continuous intravenous infusion of fluorouracil: a feasible palliative form of chemotherapy

1 reference

12 December 2020

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

12 December 2020

Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5 per cent dextrose

1 reference

12 December 2020

Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas

1 reference

12 December 2020

Continuous 5-fluorouracil infusion in refractory carcinoma of the breast

1 reference

12 December 2020

The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.259

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

8018521

1 reference